Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.22), $0.08 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $264 thousand, versus $356 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Walmart (WMT) PT Lowered to $130 at UBS as Investment Narrative's Competing Dynamics